Neurotrophic

The Effect of Lactobacillus casei Consumption in Improvement of Obsessive-Compulsive Disorder: an Animal Study.

Obsessive-compulsive disorder (OCD) is an important neuropsychiatric disorder worldwide. Common treatments of OCD include serotonergic antidepressants, which can cause potentially serious side effects. We assessed the effects of Lactobacillus casei (L. casei) Shirota consumption in an animal model of OCD. OCD-like symptoms were induced in rats by the chronic injection of the D2/D3 dopamine agonist quinpirole hydrochloride. Rats were classified into five groups of 6 rats. Four groups were injected chronically with quinpirole (0.5 mg/kg, twice weekly for 5 weeks). They were fed with L. casei Shirota (109 CF/g, daily for 4 weeks) (group 1), fluoxetine (10 mg/kg, daily for 4 weeks) (group 2), combination of L. casei Shirota and fluoxetine (group 3), and normal saline (positive control group). The last group did not receive dopamine agonist and was only injected with saline (negative control group).

Expression levels of brain-derived neurotrophic factor (Bdnf), solute carrier family 6 member 4 (Slc6a4), and 5-hydroxytryptamine receptor type 2A (Htr2a) were assessed in orbitofrontal cortex tissues of all rats. Behavioral tests showed improvement of OCD signs in rats treated with L. casei Shirota, fluoxetine, and a combination of drugs. Quantitative PCR analysis showed a remarkable decrease in the expression of Bdnf and an increase in the expression of Htr2a in quinpirole-treated rats. After treatment with L. casei Shirota and fluoxetine, the expression level of Bdnf was increased remarkably, whereas Htr2a expression was decreased. The current study showed the effectiveness of L. casei Shirota in the treatment of OCD in a rat model. The beneficial effects of this probiotic are possibly exerted through the modulation of serotonin-related genes expression.

Low brain-derived neurotrophic factor protein levels and single-nucleotide polymorphism Val66Met are associated with peripheral neuropathy in type II diabetic patients.

Studies by our group demonstrated brain-derived neurotrophic factor (BDNF) levels in blood and BDNF-Val66met-SNP as potential biomarkers in chemotherapy-induced peripheral neuropathy.

Here, we evaluate symptoms of peripheral neuropathy (PN) and depression in patients with type II diabetes mellitus in search of an association with serum BDNF levels and the Val66Met-SNP.In total, 90 patients enrolled in the study; 23 (25.6%) had known PN, as determined by nerve conduction studies (NCS-PN), and 67 (74.4%) were not diagnosed with PN (U-PN). PN symptoms were assessed and graded in these groups using the total neuropathy score (TNSr) and DN4 scales. Small nerve fiber testing of sensitivity thresholds to cold, warm and hot pain signals was performed using the Q-sense device.

Depression was assessed using the PHQ9 questionnaire. BDNF protein levels and Val66Met-SNP were determined with ELISA and Sanger sequencing, respectively.NCS-PN patients showed lower serum BDNF levels alongside significantly higher TNSr, DN4 and PHQ9 scores and lower hot pain sensitivity thresholds as compared to U-PN patients. Patients with Met-BDNF-SNP showed increased TNSr scores and lower hot pain sensitivity thresholds as compared to patients with Val-BDNF-SNP.

Depression showed a weaker correlation with sensitivity thresholds to hot pain signals as compared to TNSr and DN4 scores.Diminished peripheral BDNF resources and Met-BDNF-SNP genotype are associated with augmented symptoms of PN in patients with type II diabetes mellitus. Sensitivity thresholds to hot pain signals may be less influenced by depression and possibly more accurately detect PN symptoms in diabetic patients.

Recombinant Human Ciliary Neurotrophic Factor
7-00230	CHI Scientific	20µg	Ask for price
Recombinant Human Ciliary Neurotrophic Factor
7-00231	CHI Scientific	1mg	Ask for price
Recombinant Rat Ciliary Neurotrophic Factor
7-00235	CHI Scientific	5µg	Ask for price
Recombinant Rat Ciliary Neurotrophic Factor
7-00236	CHI Scientific	25µg	Ask for price
Recombinant Rat Ciliary Neurotrophic Factor
7-00237	CHI Scientific	1mg	Ask for price
Ciliary neurotrophic factor Polyclonal Antibody
42448-100ul	SAB	100ul	399.6 EUR
Activity-Dependent Neurotrophic Factor-14
5-00580	CHI Scientific	4 x 5mg	Ask for price
Activity – Dependent Neurotrophic Factor, ADNF
5-00581	CHI Scientific	4 x 5mg	Ask for price
Brain Injury Derived Neurotrophic Peptide
5-00866	CHI Scientific	4 x 5mg	Ask for price
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx171748	Abbexa	844.80 EUR 427.20 EUR	1 mg 200 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx171749	Abbexa	1011.60 EUR 526.80 EUR	1 mg 200 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx171750	Abbexa	1011.60 EUR 526.80 EUR	1 mg 200 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx171751	Abbexa	1011.60 EUR 526.80 EUR	1 mg 200 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx171752	Abbexa	1095.60 EUR 560.40 EUR	1 mg 200 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx134025	Abbexa	427.20 EUR 644.40 EUR 260.40 EUR	100 ul 200 ul 30 ul
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx102721	Abbexa	376.80 EUR 159.60 EUR 994.80 EUR 510.00 EUR 326.40 EUR	100 ug 10 ug 1 mg 200 ug 50 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx102722	Abbexa	493.20 EUR 159.60 EUR 1362.00 EUR 661.20 EUR 376.80 EUR	100 ug 10 ug 1 mg 200 ug 50 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx102723	Abbexa	510.00 EUR 159.60 EUR 1412.40 EUR 693.60 EUR 393.60 EUR	100 ug 10 ug 1 mg 200 ug 50 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
abx038145-100ug	Abbexa	100 ug	469.2 EUR
Ciliary Neurotrophic Factor (CNTF) Antibody
abx038378-100ug	Abbexa	100 ug	469.2 EUR
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx001565	Abbexa	493.20 EUR 710.40 EUR 218.40 EUR 376.80 EUR	100 ul 200 ul 20 ul 50 ul
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx109649	Abbexa	493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00 EUR	100 ug 1 mg 200 ug 20 ug 50 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx129965	Abbexa	543.60 EUR 159.60 EUR 1545.60 EUR 744.00 EUR 410.40 EUR	100 ug 10 ug 1 mg 200 ug 50 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx126869	Abbexa	493.20 EUR 710.40 EUR	100 ul 200 ul
Neudesin Neurotrophic Factor (NENF) Antibody
20-abx128254	Abbexa	510.00 EUR 159.60 EUR 1446.00 EUR 693.60 EUR 393.60 EUR	100 ug 10 ug 1 mg 200 ug 50 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
abx034848-400ul	Abbexa	400 ul	627.6 EUR
Ciliary Neurotrophic Factor (CNTF) Antibody
abx034848-80l	Abbexa	80 µl	343.2 EUR
Ciliary Neurotrophic Factor (CNTF) Antibody
abx037369-100ug	Abbexa	100 ug	469.2 EUR
Brain Injury Derived Neurotrophic Peptide
20-abx266438	Abbexa	661.20 EUR 1111.20 EUR 477.60 EUR	10 mg 25 mg 5 mg
Cerebral Dopamine Neurotrophic Factor Protein
20-abx261630	Abbexa	4101.60 EUR 393.60 EUR 276.00 EUR	1 mg 20 ug 5 ug
Cerebral Dopamine Neurotrophic Factor Protein
20-abx261674	Abbexa	4101.60 EUR 393.60 EUR 276.00 EUR	1 mg 20 ug 5 ug
Cerebral Dopamine Neurotrophic Factor Protein
20-abx261675	Abbexa	4101.60 EUR 393.60 EUR 276.00 EUR	1 mg 20 ug 5 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
abx431174-200ul	Abbexa	200 ul	460.8 EUR
Neudesin Neurotrophic Factor (NENF) Antibody
20-abx173748	Abbexa	1028.40 EUR 526.80 EUR	1 mg 200 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx175868	Abbexa	1362.00 EUR 661.20 EUR	1 mg 200 ug
Ciliary Neurotrophic Factor (CNTF) Antibody
20-abx175869	Abbexa	1412.40 EUR 693.60 EUR	1 mg 200 ug
BDNF/Brain-derived neurotrophic factor
E21-076	EnoGene	10ug	411.6 EUR
Brain Injury Derived Neurotrophic Peptide
H-3914.0001	Bachem	1.0mg	181.2 EUR
Description: Sum Formula: C62H102N18O18; CAS# [148330-12-5]
Brain Injury Derived Neurotrophic Peptide
H-3914.0005	Bachem	5.0mg	618 EUR
Description: Sum Formula: C62H102N18O18; CAS# [148330-12-5]
Recombinant Neudesin Neurotrophic Factor (NENF)
4-RPH544Hu01	Cloud-Clone	601.69 EUR 284.40 EUR 1926.34 EUR 722.11 EUR 1324.22 EUR 477.60 EUR 4635.84 EUR	100 ug 10ug 1 mg 200 ug 500 ug 50ug 5 mg
Description: Recombinant Human Neudesin Neurotrophic Factor expressed in: E.coli
Brain Injury Derived Neurotrophic Peptide
SP-100434-1	Alpha Diagnostics	1 mg	343.2 EUR
Ciliary Neurotrophic Factor, CNTF, human
RC218-19	Bio Basic	5ug	125.26 EUR
Recombinant Ciliary Neurotrophic Factor (CNTF)
4-RPA021Hu01	Cloud-Clone	386.65 EUR 226.80 EUR 1119.94 EUR 453.31 EUR 786.62 EUR 333.60 EUR 2619.84 EUR	100 ug 10ug 1 mg 200 ug 500 ug 50ug 5 mg
Description: Recombinant Human Ciliary Neurotrophic Factor expressed in: E.coli
Recombinant Ciliary Neurotrophic Factor (CNTF)
4-RPA021Mu01	Cloud-Clone	567.29 EUR 274.80 EUR 1797.31 EUR 679.10 EUR 1238.21 EUR 454.80 EUR 4313.28 EUR	100 ug 10ug 1 mg 200 ug 500 ug 50ug 5 mg
Description: Recombinant Mouse Ciliary Neurotrophic Factor expressed in: E.coli

Propagation of goat putative spermatogonial stem cells under growth factors defined serum-free culture conditions.

In the present study, we used a serum-free culture media to propagate goat putative spermatogonial stem cells (SSCs) and evaluated the effect of crucial growth factors on relative expression of some SSC markers and self-renewal related genes. The enriched SSCs were cultured on a homologous Sertoli cell feeder layer in KO-DMEM supplemented with 10% KOSR.

Putative SSC colonies emerged between day 6 and 10 which were then characterized by the expression of numerous spermatogonial and pluripotency related markers.

After 15 days of subculture, the relative mRNA expression study revealed that 40 ng/mL concentration of Glial cell line-derived neurotrophic factor (GDNF) upregulated the expression of BCL6B, ID4, PLZF, and UCHL1. Moreover, the supplementation of GDNF + bFGF up-regulated the expression of PLZF and BCL6B. UCHL1 expression was higher after addition of GDNF + LIF while, THY1 overexpressed in response to the addition of GDNF + CSF1. These results demonstrated that the goat SSCs were efficiently propagated using a KOSR based serum-free media and the growth factor supplementation markedly influences their gene expression profile.

Protective effects of lycopene in cancer, cardiovascular, and neurodegenerative diseases: An update on epidemiological and mechanistic perspectives.

Recent mechanistic and epidemiological studies have provided insights into health benefits of dietary lycopene to decrease the risk and complications associated with several chronic diseases such as cardiovascular diseases (CVD), obesity, type 2 diabetes, cancer, and neurodegenerative disorders. These chronic diseases are primarily associated with oxidative stress-induced systemic and low-grade chronic inflammation.

Owing to its potent antioxidant properties, lycopene can potentially alleviate enhanced levels of proinflammatory mediators (e.g., proinflammatory